Introduction: Long term oxygen therapy (LTOT) improves survival in patients with COPD with resting hypoxemia. Exacerbations (AECOPD) and hospital admissions are prevalent and have a negative impact on prognosis. The AIRVO device delivers nasal high flow (NHF) heated, humidified oxygenated air, 20-30 L/min, to COPD patients in need of LTOT.Aim: To investigate the number of self-reported AECOPD, AECOPD-related hospitalizations and all-cause mortality in LTOT COPD patients treated with AIRVO-NHF.Method: In this prospective, randomized, controlled, one-year study, 200 COPD patients treated with LTOT, were randomized to AIRVO-NHF (n=100) or usual care (n=100). Where possible, patients who ceased use of the AIRVO device were still followed. For count data, Poisson regression models were used and Cox’s proportional hazards model for all-cause mortality.Results: The two treatment groups were comparable for average days in study, age, gender, smoking status, pack years, BMI, FEV1%, 6 minutes walking test and number of exacerbations and admissions one year prior to study start. Both exacerbation rate and hospital admission rate were lower the longer patients used the Airvo device (p < 0.001). The exacerbation rate for the AIRVO-NHF group was also significantly (p<0.001) lower than for the control group in the simple group comparison without considering actual length of use of the AIRVO device. There was no difference in mortality between the two groups.Conclusion: This study shows results significantly in favor of AIRVO delivery of NHF air in reducing AECOPD exacerbations and in reducing number of hospital admissions according to actual length of use.
|Journal||European Respiratory Journal|
|Issue number||suppl 61|
|Publication status||Published - 2017|
|Event||ERS International Congress 2017 - Milan, Italy|
Duration: 9 Sep 2017 → 13 Sep 2017
|Conference||ERS International Congress 2017|
|Period||09/09/2017 → 13/09/2017|